Perfusion Extracorporeal Technology
Lifetime
4 annual accounts with figures on one time axisKey points
from the 2025 annual accountsInvestments
Green is investment, beige is depreciation.
Liquidity
Short-term debts rose from €14,322 to €24,043.
Filings
The 2022 accounts came in latest, 29 days after the end of the period.
Starting capital
Position in the sector
Lower net result than 85% of companies in office administrative support. The sector median is €15,226, over 10,284 companies.
Checked score
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 1,207 companies had the same profile as Perfusion Extracorporeal Technology has now. Each dot stands for 4 companies, two years later.
Another 0.6% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,207 companies, not a prediction for Perfusion Extracorporeal Technology. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Perfusion Extracorporeal Technology Gembloux | €32,779 | -€3,940 | 26.7% | - |
| AM BC INVEST Profondeville | €36,543 | -€6,363 | -6.2% | - |
| WILO-VET Perwez | €32,858 | -€760 | -1.0% | - |
| C2IT Antwerp | €30,570 | -€8,905 | 64.1% | - |
| SIGRID COX Herk-de-Stad | €32,770 | €1,066 | -69.0% | - |
| SELIGO Overijse | €36,105 | -€53,327 | 5.3% | - |
| MAZ2C Waterloo | €34,183 | -€27,707 | -312.5% | - |
These companies have the same main activity as Perfusion Extracorporeal Technology: other business support services (NACE 82990). They are comparable in size and age: total assets between €30,600 and €36,500, founded in 2022.
Official details
Source: KBO- Status
- Active since 14-04-2022Normal situation
- Activity
- Other business support servicesNACE 82990and 1 other
- Establishment unit
- 2.330.746.2865030 Gembloux, since 14-04-2022
- Financial year end
- 31 December
- Peppol
- Reachable since 29-12-2025
Annual accounts 2025
- €32,779▲ 10.7%
- Filing
- Filed on 11-06-2026, 50 days before the end of the filing period
Insights on Perfusion Extracorporeal Technology
Perfusion Extracorporeal Technology files the micro format. That format states no turnover. The gross margin fell from €13,859 in 2022 to -€3,940 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Perfusion Extracorporeal Technology
- What is the company number of Perfusion Extracorporeal Technology?
- The company number of Perfusion Extracorporeal Technology is 0784.827.493. The VAT number is the same number with BE in front: BE 0784.827.493.
- Where is Perfusion Extracorporeal Technology based?
- The registered office is at Rue des Haipes, Sauv. 8, 5030 Gembloux.Company details
- What does Perfusion Extracorporeal Technology do?
- According to the KBO register, the main activity is other business support services (NACE 82990).
- What is the legal form of Perfusion Extracorporeal Technology?
- Perfusion Extracorporeal Technology is a private limited company (BV).
- When was Perfusion Extracorporeal Technology founded?
- Perfusion Extracorporeal Technology was founded on 14-04-2022.
- Is Perfusion Extracorporeal Technology still active?
- Yes, Perfusion Extracorporeal Technology is an active enterprise in the KBO register.
- What is the turnover of Perfusion Extracorporeal Technology?
- The annual accounts for financial year 2025 state no turnover. The micro format does not require it.Financials
- Is Perfusion Extracorporeal Technology profitable?
- In financial year 2025, Perfusion Extracorporeal Technology made a loss of €6,541.
- Where can I find the annual accounts of Perfusion Extracorporeal Technology?
- Perfusion Extracorporeal Technology filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Perfusion Extracorporeal Technology due?
- Perfusion Extracorporeal Technology must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.